方法对比
并排查看您选择的方法；存在差异的行会高亮显示。
| 肌萎缩侧索硬化功能评定量表修订版 (ALSFRS-R)× | 多发性硬化步行量表-12 (MSWS-12)× | |
|---|---|---|
| 领域 | 神经病学 | 神经病学 |
| 方法族 | Process / pipeline | Process / pipeline |
| 起源年份≠ | 1999 | 2003 |
| 提出者≠ | James M. Cedarbaum, NIH/NINDS | Jeremy C. Hobart, University of Plymouth |
| 类型≠ | Clinician-rated and patient-reported hybrid | Self-report questionnaire |
| 开创性文献≠ | Cedarbaum, J. M., Stambler, N., Malta, E., Fuller, C., Hilt, D., Thurmond, B., & Nakanishi, A. (1999). The ALSFRS-R: A revised ALS functional rating scale that incorporates assessments of respiratory function. Journal of the Neurological Sciences, 169(1-2), 13-21. DOI ↗ | Hobart, J. C., Riazi, A., Lamping, D. L., Fitzpatrick, R., & Thompson, A. J. (2003). Measuring the impact of MS on walking ability: The 12-Item MS Walking Scale (MSWS-12). Neurology, 60(1), 31-36. DOI ↗ |
| 别名 | ALS FRS-R, Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised | MS Walking Scale-12, MSWS |
| 相关≠ | 4 | 3 |
| 摘要≠ | The ALSFRS-R is a 12-item clinician-administered functional rating scale designed to assess disease progression and functional status in amyotrophic lateral sclerosis (ALS). Introduced by Cedarbaum and colleagues in 1999, it expands upon the original ALSFRS by incorporating respiratory function assessment. It is the primary outcome measure in ALS clinical trials and routine clinical monitoring, providing quantitative tracking of disease decline that predicts survival and guides management decisions. | The MSWS-12 is a brief, patient-reported outcome measure specifically designed to assess the impact of multiple sclerosis on walking ability and limitation. Developed by Hobart and colleagues in 2003, this 12-item scale captures both the physical difficulty and functional consequences of MS-related gait impairment. It is highly responsive to change and widely used in MS clinical trials and practice as a primary outcome measure for assessing intervention effects on mobility. |
| ScholarGate数据集 ↗ |
|
|